Company Profile

Fennec Pharmaceuticals Inc. Stock Price, News & Catalysts

Ticker:
FENC
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

13.45 USD (+0.90%)

Close

Last updated: November 19, 2026

347M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, FENC closed up 0.90% at $13.45. No new same-company headline was identified in the current news window.

Company overview

Ototoxicity Prevention Company

Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.

Pediatric Commercial Foundation

PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales organization and the Fennec HEARS patient-services hub.

Expansion into Older Patients

Investigator-sponsored studies are evaluating PEDMARK in adolescent, young adult, and adult patients receiving cisplatin for head and neck, testicular, cervical, and other cancers.

Evidence Generation

Fennec supports PEDMARK commercialization with investigator-sponsored studies evaluating sodium thiosulfate across additional pediatric and young-adult settings, including evidence generation outside the United States.

Future catalysts

    Recent news

    1. 01
    2. 02
    3. 03
    4. 04
    5. 05

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    Frequently Asked Questions

    What is the current stock price of Fennec Pharmaceuticals Inc. (FENC)?

    Fennec Pharmaceuticals Inc. (FENC) most recently closed at 13.45 USD, a +0.90% move versus the previous session.

    What is the market cap of Fennec Pharmaceuticals Inc. (FENC)?

    Fennec Pharmaceuticals Inc. currently has a market capitalization of 347M USD on BioPharmSignal.

    What does Fennec Pharmaceuticals Inc. do?

    Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales...

    On which exchange is FENC stock listed?

    Fennec Pharmaceuticals Inc. (FENC) is associated with NASDAQ, United States, Biopharma.

    What is Ototoxicity?

    Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.

    Which conditions is Fennec Pharmaceuticals Inc. targeting with Ototoxicity?

    Fennec Pharmaceuticals Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

    What is Prevention?

    Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.

    What is Fennec?

    Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.